This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Skyclarys in the commercial setting and ongoing trends in Friedreich's ataxia
Ticker(s): BIIBWho's the expert?
Institution: UCLA
- Clinical Professor of Neurology. Director of Ataxia Clinic and Neurogenetics Clinical Trials at UCLA Medical Center.
- Over 30 years of experience diagnosing and treating Friedreich's Ataxia; has served on the National Ataxia Foundation's (NAF) Medical Research Advisory Board, NAF’s Board of Directors and is NAF’s Medical Director.
- Helped develop the National Ataxia Database for clinical research and has participated in 2 natural history studies (for dominant Ataxia and Friedreich’s Ataxia) in addition to numerous clinical drug trials.
Interview GoalDiscuss Skyclarys coverage, discontinuations, tolerability, etc in the commercial setting
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
